{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05761860",
            "orgStudyIdInfo": {
                "id": "IRB202300435"
            },
            "organization": {
                "fullName": "University of Florida",
                "class": "OTHER"
            },
            "briefTitle": "The Potential of Oxytocin to Reduce Opioid Abuse Liability and Pain Among Older Adults",
            "officialTitle": "The Potential of Oxytocin to Reduce Opioid Abuse Liability and Pain Among Older Adults",
            "therapeuticArea": [
                "Other"
            ],
            "study": "the-potential-of-oxytocin-to-reduce-opioid-abuse-liability-and-pain-among-older-adults"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-08",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-09-12",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-03",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-09",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-02-27",
            "studyFirstSubmitQcDate": "2023-02-27",
            "studyFirstPostDateStruct": {
                "date": "2023-03-09",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-29",
            "lastUpdatePostDateStruct": {
                "date": "2023-12-01",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "University of Florida",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Some research suggests that administration of oxytocin with oxycodone may reduce its abuse liability and improve its ability to reduce pain. In a 6-session laboratory study, we will be evaluating the effects of oxycodone and oxytocin (combined and separately, across sessions) on experimentally-induced pain, subjective effects, and decision-making.",
            "detailedDescription": "The overall project goals are to determine oxytocin effects on oxycodone's subject-rated abuse liability, and experimental pain. Generally healthy individuals (determined via medical history review and a screening session) will, after informed consent, self-administer intranasal oxytocin (or placebo, containing the same ingredients but no oxytocin) shortly after oral oxycodone or placebo in a non-residential, double-blind, randomized, placebo-controlled, within-subjects laboratory study. Prescreening will assure drug application safety and, using a validated, comprehensive pain history interview, determine previous or existing chronic pain conditions, including current pain medication use."
        },
        "conditionsModule": {
            "conditions": [
                "Pain"
            ],
            "keywords": [
                "Pain",
                "Abuse liability"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "EARLY_PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "CROSSOVER",
                "interventionModelDescription": "This is a within-participant study so that each participant receives all conditions.",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 45,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Oral oxycodone (5mg) + intranasal oxytocin (48 IU)",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Combined effects of oxycodone and oxytocin.",
                    "interventionNames": [
                        "Drug: OxyCODONE 5 mg Oral Tablet",
                        "Drug: Oxytocin Nasal Spray (48 IU)"
                    ]
                },
                {
                    "label": "Oral oxycodone (2.5mg) + intranasal oxytocin (48 IU)",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Combined effects of oxycodone and oxytocin.",
                    "interventionNames": [
                        "Drug: OxyCODONE 2.5 mg Oral Tablet",
                        "Drug: Oxytocin Nasal Spray (48 IU)"
                    ]
                },
                {
                    "label": "Oral placebo + intranasal oxytocin (48 IU)",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Separate effects of oxytocin. As is standard methodology in abuse liability and pain assessments, a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo.",
                    "interventionNames": [
                        "Other: Placebo oxyCODONE Oral Tablet",
                        "Drug: Oxytocin Nasal Spray (48 IU)"
                    ]
                },
                {
                    "label": "Oral oxycodone (5mg) + intranasal placebo",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Separate effects of oxycodone. As is standard methodology in abuse liability and pain assessments, a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo.",
                    "interventionNames": [
                        "Drug: OxyCODONE 5 mg Oral Tablet",
                        "Other: Placebo Oxytocin Nasal Spray"
                    ]
                },
                {
                    "label": "Oral oxycodone (2.5mg) + intranasal placebo",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Separate effects of oxycodone. As is standard methodology in abuse liability and pain assessments, a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo.",
                    "interventionNames": [
                        "Drug: OxyCODONE 2.5 mg Oral Tablet",
                        "Other: Placebo Oxytocin Nasal Spray"
                    ]
                },
                {
                    "label": "Oral placebo + intranasal placebo",
                    "type": "SHAM_COMPARATOR",
                    "description": "Serves as the control.",
                    "interventionNames": [
                        "Other: Placebo oxyCODONE Oral Tablet",
                        "Other: Placebo Oxytocin Nasal Spray"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "OxyCODONE 5 mg Oral Tablet",
                    "description": "Oxycodone 5mg oral administration",
                    "armGroupLabels": [
                        "Oral oxycodone (5mg) + intranasal oxytocin (48 IU)",
                        "Oral oxycodone (5mg) + intranasal placebo"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "OxyCODONE 2.5 mg Oral Tablet",
                    "description": "Oxycodone 2.5mg oral administration",
                    "armGroupLabels": [
                        "Oral oxycodone (2.5mg) + intranasal oxytocin (48 IU)",
                        "Oral oxycodone (2.5mg) + intranasal placebo"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo oxyCODONE Oral Tablet",
                    "description": "Oxycodone 0mg (placebo) oral administration",
                    "armGroupLabels": [
                        "Oral placebo + intranasal oxytocin (48 IU)",
                        "Oral placebo + intranasal placebo"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Oxytocin Nasal Spray (48 IU)",
                    "description": "Intranasal oxytocin administration (48 IU)",
                    "armGroupLabels": [
                        "Oral oxycodone (2.5mg) + intranasal oxytocin (48 IU)",
                        "Oral oxycodone (5mg) + intranasal oxytocin (48 IU)",
                        "Oral placebo + intranasal oxytocin (48 IU)"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo Oxytocin Nasal Spray",
                    "description": "Intranasal oxytocin placebo administration",
                    "armGroupLabels": [
                        "Oral oxycodone (2.5mg) + intranasal placebo",
                        "Oral oxycodone (5mg) + intranasal placebo",
                        "Oral placebo + intranasal placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Subject-rated abuse liability",
                    "description": "Using a Visual Analog Scale with scoring as 0=not at all, 20=possibly mild, 40=definitely mild, 60=moderately, 80=strongly, and 100=extremely, or any number in between. Testing occurs only in the context of 6 sessions due to a minimum of a one week washout period in between each session.",
                    "timeFrame": "Up to 6 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Individuals fluent in English will participate.\n* Must report some experience with opioids (e.g., oxycodone, defined as use at least once in the subject's lifetime).\n* Be within 20% of their ideal body weight.\n* Are not currently experiencing chronic pain (pain on most days during the past 3 months)\n* Have a systolic blood pressure of \\<=140 and diastolic blood pressure of \\<= 90, and a heart rate \\<= 90 beats per minute.\n* Participants must also have a normal electrocardiogram (EKG) reading and bloodwork indicating no major health contraindications.\n\nExclusion Criteria:\n\n* Significant current physical disease or major (uncontrolled) psychiatric disorder.\n* No self-reported current interest in drug abuse treatment.\n* Women who are pregnant or nursing.\n* Any severe comorbid illicit substance use disorders or current clinically significant withdrawal for any abused drug excluding nicotine and caffeine.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "45 Years",
            "maximumAge": "85 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Lauren E Nieder, MSPH",
                    "role": "CONTACT",
                    "phone": "(352) 294-1067",
                    "email": "lauren.nieder@ufl.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Meredith S Berry, PhD",
                    "affiliation": "University of Florida",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Florida",
                    "status": "RECRUITING",
                    "city": "Gainesville",
                    "state": "Florida",
                    "zip": "32611",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lauren E Nieder, MSPH",
                            "role": "CONTACT",
                            "phone": "352-294-1067",
                            "email": "lauren.nieder@ufl.edu"
                        },
                        {
                            "name": "Meredith S Berry, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.65163,
                        "lon": -82.32483
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009293",
                    "term": "Opioid-Related Disorders"
                }
            ],
            "ancestors": [
                {
                    "id": "D000079524",
                    "term": "Narcotic-Related Disorders"
                },
                {
                    "id": "D000019966",
                    "term": "Substance-Related Disorders"
                },
                {
                    "id": "D000064419",
                    "term": "Chemically-Induced Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M13066",
                    "name": "Pain",
                    "relevance": "LOW"
                },
                {
                    "id": "M12244",
                    "name": "Opioid-Related Disorders",
                    "asFound": "Opioid Abuse",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2057",
                    "name": "Narcotic-Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M21837",
                    "name": "Substance-Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M30302",
                    "name": "Chemically-Induced Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC25",
                    "name": "Substance Related Disorders"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000010098",
                    "term": "Oxycodone"
                },
                {
                    "id": "D000010121",
                    "term": "Oxytocin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000010120",
                    "term": "Oxytocics"
                },
                {
                    "id": "D000012102",
                    "term": "Reproductive Control Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000701",
                    "term": "Analgesics, Opioid"
                },
                {
                    "id": "D000009294",
                    "term": "Narcotics"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000000700",
                    "term": "Analgesics"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4033",
                    "name": "Analgesics, Opioid",
                    "relevance": "LOW"
                },
                {
                    "id": "M13020",
                    "name": "Oxycodone",
                    "asFound": "Where",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13041",
                    "name": "Oxytocin",
                    "asFound": "State",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4032",
                    "name": "Analgesics",
                    "relevance": "LOW"
                },
                {
                    "id": "M12245",
                    "name": "Narcotics",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Repr",
                    "name": "Reproductive Control Agents"
                }
            ]
        }
    },
    "hasResults": false
}